Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 35380647.
- Also identified by DOI 10.1001/jamanetworkopen.2022.5750 and PMC identifier 8984772.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.
Medical subject headings
- COVID-19